ArticleBrain communications2021
Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging.
Article in Brain communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- The Alzheimer's Disease Diagnosis and Plasma Phospho-Tau217 (ADAPT) study stage 1: Validating clinical cut-points against CSF and amyloid PET.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Identification of Hasegawa Dementia Scale-Revised Cutoff Scores Associated With Mini-Mental State Examination Thresholds for Anti-Amyloid β Therapies in Patients With Amnesia.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2025Article
- Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Exploring the Complex Relationship Between Antidepressants, Depression and Neurocognitive Disorders.Biomedicines · 2024Review
- Distinguishing features of depression in dementia from primary psychiatric disease.Discover mental health · 2024Review
- Visual atrophy rating scales and amyloid PET status in an Alzheimer's disease clinical cohort.Annals of clinical and translational neurology · 2023Review
- Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging.Insights into imaging · 2023Review
- Assessment of memory deficits in psychiatric disorders: A systematic literature review.Journal of neurosciences in rural practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Episodic memory impairment and brain amyloid-beta are two of the main hallmarks of Alzheimer's Disease. In the clinical setting, these are often evaluated through neuropsychological testing and amyloid PET imaging, respectively. The use of amyloid PET in clinical practice is only indicated in patients with substantial diagnostic uncertainty due to atypical clinical presentation, multiple comorbidities and/or early age of onset. The relationship between amyloid-beta and cognition has been previously investigated, but no study has examined how neuropsychological features relate to the presence of amyloid pathology in the clinical population that meets the appropriate use criteria for amyloid PET imaging. In this study, we evaluated a clinical cohort of patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.